NP Medical News about Sciatica Lornoxicam

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Efficacy and safety of lornoxicam compared with placebo and diclofenac in acute sciatica/lumbo-sciatica: an analysis from a randomised, double-blind, multicentre, parallel-group study
International Journal of Clinical Practice, 10/12/09

Herrmann WA et al. – These data indicate that the analgesic efficacy of lornoxicam (LNX) is superior to placebo and similar to diclofenac in acute sciatica/lumbo–sciatica.

Methods

Male or female patients (n = 171) aged 18–70 years with acute sciatica or lumbo–sciatica.
The dosage of study treatment was 8–24 mg/day LNX, 100–150 mg/day diclofenac or placebo.

Results

In total, 164 patients completed the study.
Significant differences in PID between LNX and placebo were seen in the time interval 3–8 h after the first dose including pain intensity difference from baseline to 6 h (PID0–6 h).
Secondary end–points favoured LNX vs. placebo, but in general were not significantly different.
LNX and diclofenac had similar analgesic effect. Incidence and severity of adverse events were comparable for the three treatments; overall tolerability was rated as very good/good by 93% of the patients.

<< Previous
Optimal gestational weight gain ranges for the avoidance of...

Next >>
Withholding and Withdrawing Life-Sustaining Treatment in Advanced...